Aethlon Medical (AEMD) Emerging Growth Conference 91 summary

Clinical trial overview

• Ongoing oncology trial in Australia targets patients with solid tumors unresponsive to anti-PD-1 immunotherapies like Keytruda or Opdivo.

• Study design includes three cohorts, each receiving increasing numbers of Hemopurifier (HP) treatments per week.

• Primary endpoint is safety, with additional focus on optimal HP treatment frequency and reduction of extracellular vesicles (EVs).

Recent developments and data

• Data Safety Monitoring Board (DSMB) reviewed cohort two and recommended advancing to the third and final cohort.

• Favorable trends in EV and immune cell numbers observed in the first cohort after a single HP treatment.

• Data from cohort two on EV and T cell numbers expected this quarter.

Next steps and logistics

• Enrollment for the third cohort is underway, with timing coordinated to precede patients' scheduled immunotherapy treatments.

• Hospitals are managing logistical challenges to align HP treatments with patients' existing therapy schedules.

• Anticipated completion of third cohort enrollment within the current quarter.